{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T12:20:44Z","timestamp":1774786844035,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.vaccine.2008.07.034","type":"journal-article","created":{"date-parts":[[2008,8,4]],"date-time":"2008-08-04T13:45:30Z","timestamp":1217857530000},"page":"5527-5534","source":"Crossref","is-referenced-by-count":26,"title":["Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants"],"prefix":"10.1016","volume":"26","author":[{"given":"Qi","family":"Qiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard Yuan-Hu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanmao","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminaka","family":"Sugauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Grandinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey J.","family":"Alter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Wai-Kuo","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5424","key":"10.1016\/j.vaccine.2008.07.034_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1126\/science.285.5424.26","article-title":"The scientific challenge of hepatitis C","volume":"285","author":"Cohen","year":"1999","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2008.07.034_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2008.07.034_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2000-9505","article-title":"Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome","volume":"20","author":"Alter","year":"2000","journal-title":"Semin Liver Dis"},{"issue":"9286","key":"10.1016\/j.vaccine.2008.07.034_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.vaccine.2008.07.034_bib5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2008.07.034_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2893.1999.00008.x","article-title":"Cellular immune response to the hepatitis C virus","volume":"6","author":"Rehermann","year":"1999","journal-title":"J Viral Hepat"},{"issue":"8","key":"10.1016\/j.vaccine.2008.07.034_bib7","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1073\/pnas.89.8.3468","article-title":"Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections","volume":"89","author":"Weiner","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"10.1016\/j.vaccine.2008.07.034_bib8","doi-asserted-by":"crossref","first-page":"14199","DOI":"10.1073\/pnas.2335981100","article-title":"In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes","volume":"100","author":"Bartosch","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"27","key":"10.1016\/j.vaccine.2008.07.034_bib9","doi-asserted-by":"crossref","first-page":"10149","DOI":"10.1073\/pnas.0403519101","article-title":"Neutralizing antibody response during acute and chronic hepatitis C virus infection","volume":"101","author":"Logvinoff","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"10.1016\/j.vaccine.2008.07.034_bib10","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1073\/pnas.0402458101","article-title":"Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma","volume":"101","author":"Yu","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5734","key":"10.1016\/j.vaccine.2008.07.034_bib11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.vaccine.2008.07.034_bib12","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vitro","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.vaccine.2008.07.034_bib13","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.194.10.1395","article-title":"Determinants of viral clearance and persistence during acute hepatitis C virus infection","volume":"194","author":"Thimme","year":"2001","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2008.07.034_bib14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0016-5085(99)70353-7","article-title":"Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C","volume":"117","author":"Gerlach","year":"1999","journal-title":"Gastroenterology"},{"issue":"8981","key":"10.1016\/j.vaccine.2008.07.034_bib15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0140-6736(95)91691-1","article-title":"Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection","volume":"346","author":"Diepolder","year":"1995","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2008.07.034_bib16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/75063","article-title":"Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C","volume":"6","author":"Takaki","year":"2000","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.vaccine.2008.07.034_bib17","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S1471-4906(03)00178-9","article-title":"Hepatitis C virus infection: when silence is deception","volume":"24","author":"Racanelli","year":"2003","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2008.07.034_bib18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/gast.2001.27024","article-title":"Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response","volume":"121","author":"Kamal","year":"2001","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.vaccine.2008.07.034_bib19","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4049\/jimmunol.159.2.1012","article-title":"CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes","volume":"159","author":"Woitas","year":"1997","journal-title":"J Immunol"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2008.07.034_bib20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1099\/vir.0.79896-0","article-title":"Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes","volume":"85","author":"Jiao","year":"2004","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2008.07.034_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expert Rev Vaccines"},{"issue":"30","key":"10.1016\/j.vaccine.2008.07.034_bib22","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1016\/S0264-410X(01)00111-6","article-title":"A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers","volume":"19","author":"Toledo","year":"2001","journal-title":"Vaccine"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2008.07.034_bib23","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1016\/S0264-410X(99)00175-9","article-title":"Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant","volume":"17","author":"Saul","year":"1999","journal-title":"Vaccine"},{"issue":"6813","key":"10.1016\/j.vaccine.2008.07.034_bib24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.vaccine.2008.07.034_bib25","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1002\/1521-4141(200012)30:12<3591::AID-IMMU3591>3.0.CO;2-J","article-title":"Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins","volume":"30","author":"Sparwasser","year":"2000","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2008.07.034_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1053\/jhep.2001.26523","article-title":"Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice","volume":"34","author":"Lechmann","year":"2001","journal-title":"Hepatology"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2008.07.034_bib27","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1099\/vir.0.79821-0","article-title":"Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3","volume":"85","author":"Yu","year":"2004","journal-title":"J Gen Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2008.07.034_bib28","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.186.10.1623","article-title":"CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity","volume":"186","author":"Chu","year":"1997","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.vaccine.2008.07.034_bib29","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.20020147","article-title":"Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection","volume":"195","author":"Rhee","year":"2002","journal-title":"J Exp Med"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2008.07.034_bib30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0161-5890(96)00010-7","article-title":"Identification of a murine CD4+ T-lymphocyte response site in hepatitis C virus core protein","volume":"33","author":"Chen","year":"1996","journal-title":"Mol Immunol"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2008.07.034_bib31","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1016\/S0264-410X(99)00130-9","article-title":"Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization","volume":"17","author":"Hu","year":"1999","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2008.07.034_bib32","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1128\/JVI.67.8.4566-4579.1993","article-title":"Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli","volume":"67","author":"Luckow","year":"1993","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2008.07.034_bib33","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1128\/JVI.72.5.3827-3836.1998","article-title":"Hepatitis C virus structural proteins assemble into viruslike particles in insect cells","volume":"72","author":"Baumert","year":"1998","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2008.07.034_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1352-0504.2003.00464.x","article-title":"DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response","volume":"11","author":"Jiao","year":"2004","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.vaccine.2008.07.034_bib35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1053\/jhep.2003.50051","article-title":"Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization","volume":"37","author":"Jiao","year":"2003","journal-title":"Hepatology"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2008.07.034_bib36","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1099\/0022-1317-81-12-2873","article-title":"Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding","volume":"81","author":"Patel","year":"2000","journal-title":"J Gen Virol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2008.07.034_bib37","first-page":"97","article-title":"Signal transduction induced by immunostimulatory CpG DNA","volume":"22","author":"Krieg","year":"2000","journal-title":"Springer Semin Immunopathol"},{"issue":"1","key":"10.1016\/j.vaccine.2008.07.034_bib38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4049\/jimmunol.167.1.66","article-title":"Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells","volume":"167","author":"Shirota","year":"2001","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2008.07.034_bib39","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.164.3.1617","article-title":"Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo","volume":"164","author":"Hartmann","year":"2000","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2008.07.034_bib40","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.4049\/jimmunol.168.4.1659","article-title":"CpG oligodeoxynucleotides as vaccine adjuvants in primates","volume":"168","author":"Verthelyi","year":"2002","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2008.07.034_bib41","doi-asserted-by":"crossref","first-page":"944","DOI":"10.4049\/jimmunol.164.2.944","article-title":"Mechanism and function of a newly identified CpG DNA motif in human primary B cells","volume":"164","author":"Hartmann","year":"2000","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2008.07.034_bib42","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4049\/jimmunol.160.2.870","article-title":"CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen","volume":"160","author":"Davis","year":"1998","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2008.07.034_bib43","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1128\/JVI.70.8.5177-5182.1996","article-title":"Interaction between hepatitis C virus core protein and E1 envelope protein","volume":"70","author":"Lo","year":"1996","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08009328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08009328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T12:24:56Z","timestamp":1684499096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X08009328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":43,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0264410X08009328"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.07.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}